标题
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
作者
关键词
-
出版物
NATURE
Volume 538, Issue 7626, Pages 477-482
出版商
Springer Nature
发表日期
2016-10-18
DOI
10.1038/nature19830
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods
- (2016) Nicholas F. Pelz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance
- (2016) S Spinner et al. LEUKEMIA
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy
- (2016) Duong Nhu et al. MedChemComm
- MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis
- (2015) A. Lazareth et al. HAEMATOLOGICA
- Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
- (2015) Milan Bruncko et al. JOURNAL OF MEDICINAL CHEMISTRY
- MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
- (2015) Y. Xiao et al. MOLECULAR CANCER THERAPEUTICS
- Cell Death Signaling
- (2015) Douglas R. Green et al. Cold Spring Harbor Perspectives in Biology
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo
- (2015) Brandon J. Aubrey et al. Cell Reports
- MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis
- (2015) A. Lazareth et al. HAEMATOLOGICA
- MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice
- (2014) S. Grabow et al. BLOOD
- Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
- (2014) G. L. Kelly et al. GENES & DEVELOPMENT
- Off-Rate Screening (ORS) By Surface Plasmon Resonance. An Efficient Method to Kinetically Sample Hit to Lead Chemical Space from Unpurified Reaction Products
- (2014) James B. Murray et al. JOURNAL OF MEDICINAL CHEMISTRY
- Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1)
- (2014) Chao Fang et al. ACS Medicinal Chemistry Letters
- Fragment Screening by Weak Affinity Chromatography: Comparison with Established Techniques for Screening against HSP90
- (2013) Elinor Meiby et al. ANALYTICAL CHEMISTRY
- Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia
- (2013) B. Koss et al. BLOOD
- Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure
- (2013) R. L. Thomas et al. GENES & DEVELOPMENT
- Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
- (2013) X. Wang et al. GENES & DEVELOPMENT
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency
- (2012) Guo Wei et al. CANCER CELL
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration
- (2012) Rhonda M. Perciavalle et al. NATURE CELL BIOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- XDS
- (2010) Wolfgang Kabsch ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520
- (2010) B. J. Tunquist et al. MOLECULAR CANCER THERAPEUTICS
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines
- (2010) H Zhang et al. ONCOGENE
- Mcl-1 is a potential therapeutic target in multiple types of cancer
- (2008) C. Akgul CELLULAR AND MOLECULAR LIFE SCIENCES
- A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation
- (2008) Erinna F. Lee et al. JOURNAL OF CELL BIOLOGY
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
- (2008) Mark S. Cragg et al. JOURNAL OF CLINICAL INVESTIGATION
- BCL-2 family antagonists for cancer therapy
- (2008) Guillaume Lessene et al. NATURE REVIEWS DRUG DISCOVERY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now